Articles

Poll

Podcasts

Slideshows

Videos

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

An economic analysis highlights a cardiovascular polypill's potential to lower healthcare costs and address income-based health disparities.

Polypill Therapy Cost-Effective for CVD Risk in Underserved Populations

This listicle highlights 5 major approvals and 5 trial updates in cardiovascular care from 2024.

Cardiology Year in Review: 2024

Nathan D. Wong, MPH, PhD discusses the evolution of Lp(a) in risk assessment, given its role as a genetic risk factor for cardiovascular complications.

Nathan D. Wong, MPH, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment 

Laurence Sperling, MD shares insights into a multi-disciplinary approach to the management of obesity from the perspective of a cardiologist.

Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic

Matthew J. Budoff, MD describes bridging the gap between atherosclerosis and osteoporosis through advanced Imaging techniques.

Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis

Stephen J. Nicholls, MD, PhD discusses the robust efficacy and tolerability of zerlasiran for Lp(a) lowering, paving the way for Phase 3 development.

Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD

Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with diabetes in the BPROAD trial.

Intensive Blood Pressure Regimen Lowers CVD Risk in People with T2D 

A 6-year longitudinal study, involving more than 200,000 adults, reported a notable rise in dyslipidemia incidence during the COVID-19 pandemic.

COVID-19 Pandemic Linked to 29% Higher Risk of Dyslipidemia, Study Finds

A new AHA statement highlights the benefits of lipoprotein apheresis for familial hypercholesterolemia and urges broader access to the underutilized therapy.

AHA Scientific Statement Promotes Expanded Use of Lipoprotein Apheresis 

Elucid has received 510(k) clearance for its PlaqueIQ™ imaging analysis software to help physicians diagnose cardiovascular disease.

Atherosclerotic Cardiovascular Disease